Table 2.
Tumor Responses per Investigator and BICR Assessment (mRECIST)
| Best Response, n (%) | Triple Therapy (n=62) | |
|---|---|---|
| Investigator | BICR | |
| Complete response | 20 (30.6) | 17 (27.4) |
| Partial response | 30 (50) | 31 (50) |
| Stable disease | 8 (12.9) | 9 (14.5) |
| Progressive disease | 4 (6.5) | 4 (6.5) |
| Not evaluable | 0 | 1 (1.6) |
| Objective response rate, n (%) | 50 (80.6) | 48 (77.4) |
| Disease control rate, n (%) | 58 (93.5) | 57 (91.9) |
Abbreviations: BICR, blinded independent central review; mRECIST, modified Response Evaluation Criteria in Solid Tumors.